



EHR4CR

Electronic Health Record Systems for Clinical Research

Andreas Schmidt, F Hoffmann-La Roche Inc. Switzerland on behalf of the EHR4CR consortium







What patients need What Europe needs



- To expand the use of EHR data for research, in Europe, to realize the potential of enhanced academic research, drug development, and safety
 - backed by a business model for sustainability
- There is a gap between:
 - technology solutions,
 - regional diversity, individual approaches and
 - the lack of a common viable business model across Europe
- EHR data offers large opportunities for the advancement of medical research, the improvement of healthcare, and the enhancement of patient safety.



Innovative approach



- EHR4CR will move beyond the current state-of-the-art by combining previously isolated informatics progress - e.g. semantic interoperability, privacy enhancing techniques, and interoperability standards) with an entirely new approach to reusing EHR data for supporting medical research, underpinned by a comprehensive business model for governance, acceptance, adoption and sustainability.
- The project will demonstrate the viability and scalability of the EHR4CR business model through pilots - e.g. platform services designed for protocol feasibility, patient recruitment, and clinical trial data capture.
- The EHR4CR will be the largest public-private partnership to date with the goal to tie interoperability aspects together, to provide adaptable, reusable and scalable solutions and be the first step to a pan-EU capability for clinical research with integrated interoperability for clinics across countries in Europe.



Results/Achievements so far



- Negotiation and legal work timely completed with 34 consortium partners to become 3rd out of nine 2009 projects to have kicked-off 3rd/4th March 2011
- Various Workpackage groups, Advisory Board and Ethics Committee being mobilized
- First workshop conducted on scenario based requirements gathering
- Integrated project plan being established
- Business Model Innovation Strategic Forum concept being implemented
- Environmental scan of key external stakeholders incl. Patient advocacy groups, Health agencies etc. in preparation.



Time and money



Financing

IMI funding: € 7.019.046

EFPIA, mainly in-kind contribution: € 7.042.616

• Others: € 1.989.852

Total project cost: €16 million
€ 16.051.514

Timing:

Starting date: 1st March 2011

Duration: 4 years



Consortium Partners




















NOVARTIS





University of Dundee






































WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER





Further information



- Contacts <u>Mats.Sundgren@astrazeneca.com</u> <u>georges.demoor@UGent.be</u> <u>Andreas.Schmidt.as3@Roche.com</u>
- Press inquiries <u>press@ehr4cr.eu</u>



- Project website http://ehr4cr.eurorec.org/index.cfm
- Fact sheet at IMI website:





www.imi.europa.eu